Contract notice CN3924657 · National Blood Authority
Imported Plasma and Recombinant Products
$30m
whole-of-life value, after 1 amendment
+$18m (+156.1%) since first published at $12m
- Supplier
- Takeda Pharmaceuticals Australia Pty Ltd ABN 71095610870
- Agency
- National Blood Authority
- Procurement method
- limited tender
- Exemption
- App A: 11. Blood plasma products or plasma fractionation services.
- Term
- 2022-10-01 to 2027-09-30
- Published
- 2022-11-02
- Category (UNSPSC)
- 51000000
- Agency reference
- CBP-CON-00172
Worth a closer look
Value increased after award: +156% on first published value. Agencies must publish amendments that change a contract’s value. Large increases can mean the original scope or price was understated.
Common explanations: Additional work or an extended term agreed after award. Options in the original contract that were later taken up. A correction to a value entered wrongly.
Value by financial year
The total value spread evenly from start to end date. estimate: annualised
| Financial year | Estimated amount |
|---|---|
| 2022-23 | $4.5m |
| 2023-24 | $6.1m |
| 2024-25 | $6.0m |
| 2025-26 | $6.0m |
| 2026-27 | $6.0m |
| 2027-28 | $1.5m |
Published versions
Every version of this notice we have loaded. Source: AusTender OCDS API.
| Date | Version | Value |
|---|---|---|
| 2022-11-02 | original notice | $12m |
| 2026-07-16 | amendment | $30m |